Psychopharmacology

, Volume 232, Issue 7, pp 1325–1336 | Cite as

Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder

  • Francesco Benedetti
  • Sara Poletti
  • Daniele Radaelli
  • Clara Locatelli
  • Adele Pirovano
  • Cristina Lorenzi
  • Benedetta Vai
  • Irene Bollettini
  • Andrea Falini
  • Enrico Smeraldi
  • Cristina Colombo
Original Investigation

Abstract

Rationale

Lithium is the mainstay for the treatment of bipolar disorder (BD) and inhibits glycogen synthase kinase-3β (GSK-3β). The less active GSK-3β promoter gene variants have been associated with less detrimental clinical features of BD. GSK-3β gene variants and lithium can influence brain gray and white matter structure in psychiatric conditions, so we studied their combined effect in BD.

Objectives

The aim of this study is to investigate the effects of ongoing long-term lithium treatment and GSK-3β promoter rs334558 polymorphism on regional gray matter (GM) volumes of patients with BD.

Materials and methods

GM volumes were estimated with 3.0 Tesla MRI in 150 patients affected by a major depressive episode in course of BD. Duration of lifetime lithium treatment was retrospectively assessed. Analyses were performed by searching for significant effects of lithium and rs334558 in the whole brain.

Results

The less active GSK-3β rs334558*G gene promoter variant and the long-term administration of lithium were synergistically associated with increased GM volumes in the right frontal lobe, in a large cluster encompassing the boundaries of subgenual and orbitofrontal cortex (including Brodmann areas 25, 11, and 47). Effects of lithium on GM revealed in rs334558*G carriers only, consistent with previously reported clinical effects in these genotype groups, and were proportional to the duration of treatment.

Conclusions

Lithium and rs334558 influenced GM volumes in areas critical for the generation and control of affect, which have been widely implicated in the process of BD pathophysiology. In the light of the protective effects of lithium on white matter integrity, our results suggest that the clinical effects of lithium associate with a neurotrophic effect on the whole brain, probably mediated by GSK-3β inhibition.

Keywords

Lithium GSK-3β Neuroplasticity Bipolar disorder Gray matter 

Notes

Authors and contributors

All individuals included as authors of papers contributed substantially to the scientific process leading up to the writing of the paper. FB designed the study. ES, CC, FB, and AF obtained the funding. CL and CC were involved in participants’ recruitment and selection and collected the clinical data. SP, DR, IB, and BV carried out the brain imaging scanning with the neuroradiological supervision of AF and post-processed the images. SP carried out the imaging-genetic analysis with contributions from FB. CL and AP performed the genotyping. FB wrote the first draft of the manuscript. FB and SP had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors take final responsibility for the decision to submit for publication. The authors are entirely responsible for the scientific content of the paper.

Funding

The CERMAC received research grants from the Italian Ministry of University and Scientific Research, from the Italian Ministry of Health, from the European Union (FP7 grant 222963), from Trenta ore per la Vita Association, and from Janssen-Cilag.

Conflict of interest

None of the authors have conflicts of interest.

References

  1. Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz A, Bauer M (2007) Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry 62:1295–1302CrossRefPubMedGoogle Scholar
  2. Altshuler LL, Kupka RW, Hellemann G, Frye MA, Sugar CA, McElroy SL, Nolen WA, Grunze H, Leverich GS, Keck PE, Zermeno M, Post RM, Suppes T (2010) Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network. Am J Psychiatry 167:708–715CrossRefPubMedGoogle Scholar
  3. Ashburner J (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38:95–113CrossRefPubMedGoogle Scholar
  4. Azim K, Butt AM (2011) GSK3beta negatively regulates oligodendrocyte differentiation and myelination in vivo. Glia 59:540–553CrossRefPubMedGoogle Scholar
  5. Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M, Trakhtenbroit M, Glahn DC, Brambilla P, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Soares JC (2007) Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 62:7–16CrossRefPubMedCentralPubMedGoogle Scholar
  6. Beaulieu JM (2012) A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 37:7–16CrossRefPubMedCentralPubMedGoogle Scholar
  7. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101:5099–5104CrossRefPubMedCentralPubMedGoogle Scholar
  8. Beaulieu JM, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327–347CrossRefPubMedGoogle Scholar
  9. Benedetti F, Bernasconi A, Lorenzi C, Pontiggia A, Serretti A, Colombo C, Smeraldi E (2004a) A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 355:37–40CrossRefPubMedGoogle Scholar
  10. Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E (2004b) A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 368:123–126CrossRefPubMedGoogle Scholar
  11. Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C, Smeraldi E (2005) Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 376:51–55CrossRefPubMedGoogle Scholar
  12. Benedetti F, Poletti S, Radaelli D, Bernasconi A, Cavallaro R, Falini A, Lorenzi C, Pirovano A, Dallaspezia S, Locatelli C, Scotti G, Smeraldi E (2010) Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity. Genes Brain Behav 9:365–371CrossRefPubMedGoogle Scholar
  13. Benedetti F, Absinta M, Rocca MA, Radaelli D, Poletti S, Bernasconi A, Dallaspezia S, Pagani E, Falini A, Copetti M, Colombo C, Comi G, Smeraldi E, Filippi M (2011a) Tract-specific white matter structural disruption in patients with bipolar disorder. Bipolar Disord 13:414–424CrossRefPubMedGoogle Scholar
  14. Benedetti F, Radaelli D, Poletti S, Locatelli C, Falini A, Colombo C, Smeraldi E (2011b) Opposite effects of suicidality and lithium on gray matter volumes in bipolar depression. J Affect Disord 135:139–147CrossRefPubMedGoogle Scholar
  15. Benedetti F, Yeh PH, Bellani M, Radaelli D, Nicoletti MA, Poletti S, Falini A, Dallaspezia S, Colombo C, Scotti G, Smeraldi E, Soares JC, Brambilla P (2011c) Disruption of white matter integrity in bipolar depression as a possible structural marker of illness. Biol Psychiatry 69:309–317CrossRefPubMedGoogle Scholar
  16. Benedetti F, Bollettini I, Barberi I, Radaelli D, Poletti S, Locatelli C, Pirovano A, Lorenzi C, Falini A, Colombo C, Smeraldi E (2013) Lithium and GSK3-beta promoter gene variants influence white matter microstructure in bipolar disorder. Neuropsychopharmacology 38:313–327CrossRefPubMedCentralPubMedGoogle Scholar
  17. Benedetti F, Bollettini I, Radaelli D, Poletti S, Locatelli C, Falini A, Smeraldi E, Colombo C (2014) Adverse childhood experiences influence white matter microstructure in patients with bipolar disorder. Psychol MedGoogle Scholar
  18. Benes FM, Paskevich PA, Davidson J, Domesick VB (1985) Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats. Brain Res 348:15–20CrossRefPubMedGoogle Scholar
  19. Bora E, Fornito A, Yucel M, Pantelis C (2010) Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol Psychiatry 67:1097–1105CrossRefPubMedGoogle Scholar
  20. Boretius S, Escher A, Dallenga T, Wrzos C, Tammer R, Bruck W, Nessler S, Frahm J, Stadelmann C (2012) Assessment of lesion pathology in a new animal model of MS by multiparametric MRI and DTI. Neuroimage 59:2678–2688CrossRefPubMedGoogle Scholar
  21. Brooks JO 3rd, Bonner JC, Rosen AC, Wang PW, Hoblyn JC, Hill SJ, Ketter TA (2009) Dorsolateral and dorsomedial prefrontal gray matter density changes associated with bipolar depression. Psychiatry Res 172:200–204CrossRefPubMedCentralPubMedGoogle Scholar
  22. Carter RM, Huettel SA (2013) A nexus model of the temporal-parietal junction. Trends Cogn Sci 17:328–336CrossRefPubMedCentralPubMedGoogle Scholar
  23. Chiu CT, Chuang DM (2010) Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128:281–304CrossRefPubMedCentralPubMedGoogle Scholar
  24. Cole AR (2013) Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia. FEBS J 280:5213–5227CrossRefPubMedGoogle Scholar
  25. Coryell W, Nopoulos P, Drevets W, Wilson T, Andreasen NC (2005) Subgenual prefrontal cortex volumes in major depressive disorder and schizophrenia: diagnostic specificity and prognostic implications. Am J Psychiatry 162:1706–1712CrossRefPubMedGoogle Scholar
  26. Cousins DA, Aribisala B, Nicol Ferrier I, Blamire AM (2013) Lithium, gray matter, and magnetic resonance imaging signal. Biol Psychiatry 73:652–657CrossRefPubMedGoogle Scholar
  27. Dill J, Wang H, Zhou F, Li S (2008) Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. J Neurosci 28:8914–8928CrossRefPubMedGoogle Scholar
  28. Drevets WC, Price JL, Simpson JRJ, Todd RD, Reich T, Vannier M et al (1997) Subgenual prefrontal cortex abnormalities in mood disorders. Nature 38:824–827CrossRefGoogle Scholar
  29. Drevets WC, Savitz J, Trimble M (2008) The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 13:663–681PubMedCentralPubMedGoogle Scholar
  30. Du J, Wei Y, Liu L, Wang Y, Khairova R, Blumenthal R, Tragon T, Hunsberger JG, Machado-Vieira R, Drevets W, Wang YT, Manji HK (2010) A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A 107:11573–11578CrossRefPubMedCentralPubMedGoogle Scholar
  31. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68–72CrossRefPubMedGoogle Scholar
  32. Eker C, Simsek F, Yilmazer EE, Kitis O, Cinar C, Eker OD, Coburn K, Gonul AS (2014) Brain regions associated with risk and resistance for bipolar I disorder: a voxel-based MRI study of patients with bipolar disorder and their healthy siblings. Bipolar DisordGoogle Scholar
  33. Forde JE, Dale TC (2007) Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 64:1930–1944CrossRefPubMedGoogle Scholar
  34. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001) A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14:21–36CrossRefPubMedGoogle Scholar
  35. Gould TD, Manji HK (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30:1223–1237PubMedGoogle Scholar
  36. Gould TD, Picchini AM, Einat H, Manji HK (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 7:1399–1409CrossRefPubMedGoogle Scholar
  37. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391–426CrossRefPubMedGoogle Scholar
  38. Hill T, Lewicki P (2006) Statistics: methods and applications. A comprehensive reference for science, industry, and data mining. General linear models, StatSoft, Tulsa (OK) Chapter 18:245–276Google Scholar
  39. Hughett P (2007) Accurate computation of the F-to-z and t-to-z transforms for large arguments. J Stat Softw 23Google Scholar
  40. Hunsberger JG, Austin DR, Chen G, Manji HK (2009) Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. Brain Res 1293:76–84CrossRefPubMedCentralPubMedGoogle Scholar
  41. Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P, Matthews PM (2009) Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry 66:721–728CrossRefPubMedGoogle Scholar
  42. Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P, Matthews PM (2010) Pathway-based approaches to imaging genetics association studies: Wnt signaling, GSK3beta substrates and major depression. Neuroimage 53:908–917CrossRefPubMedGoogle Scholar
  43. Janssen J, Hulshoff Pol HE, Schnack HG, Kok RM, Lampe IK, de Leeuw FE, Kahn RS, Heeren TJ (2007) Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression. Int J Geriatr Psychiatry 22:468–474CrossRefPubMedGoogle Scholar
  44. Kinoshita Y, Ohnishi A, Kohshi K, Yokota A (1999) Apparent diffusion coefficient on rat brain and nerves intoxicated with methylmercury. Environ Res 80:348–354CrossRefPubMedGoogle Scholar
  45. Klein A, Andersson J, Ardekani BA, Ashburner J, Avants B, Chiang MC, Christensen GE, Collins DL, Gee J, Hellier P, Song JH, Jenkinson M, Lepage C, Rueckert D, Thompson P, Vercauteren T, Woods RP, Mann JJ, Parsey RV (2009) Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 46:786–802CrossRefPubMedCentralPubMedGoogle Scholar
  46. Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA (2007) Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 32:1216–1223CrossRefPubMedGoogle Scholar
  47. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, Frye MA, Keck PE Jr, McElroy SL, Grunze H, Post RM (2007) Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 9:531–535CrossRefPubMedGoogle Scholar
  48. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD, Buchanan DD, Silburn PA, Halliday GM, Schofield PR (2005) GSK3B polymorphisms alter transcription and splicing in Parkinson’s disease. Ann Neurol 58:829–839CrossRefPubMedGoogle Scholar
  49. Lai CH, Wu YT (2013) Changes in gray matter volume of remitted first-episode, drug-naive, panic disorder patients after 6-week antidepressant therapy. J Psychiatr Res 47:122–127CrossRefPubMedGoogle Scholar
  50. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, Kochunov PV, Nickerson D, Mikiten SA, Fox PT (2000) Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 10:120–131CrossRefPubMedGoogle Scholar
  51. Leckman JFSD, Thompson WD, Belanger A, Weissman MM (1982) Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry 39:879–883CrossRefPubMedGoogle Scholar
  52. Lee AL, Ogle WO, Sapolsky RM (2002) Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 4:117–128CrossRefPubMedGoogle Scholar
  53. Li X, Jope RS (2010) Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 35:2143–2154CrossRefPubMedCentralPubMedGoogle Scholar
  54. Lim L, Radua J, Rubia K (2014) Gray matter abnormalities in childhood maltreatment: a voxel-wise meta-analysis. Am J PsychiatryGoogle Scholar
  55. Lin YF, Huang MC, Liu HC (2013) Glycogen synthase kinase 3beta gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J Affect Disord 147:401–406CrossRefPubMedGoogle Scholar
  56. Lyoo IK, Dager SR, Kim JE, Yoon SJ, Friedman SD, Dunner DL, Renshaw PF (2010) Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology 35:1743–1750PubMedCentralPubMedGoogle Scholar
  57. Manji HK, Moore GJ, Rajkowska G, Chen G (2000) Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 5:578–593Google Scholar
  58. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT (1999) Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 156:675–682PubMedGoogle Scholar
  59. McCulloch CE, Searle SR, Neuhaus JM (2008) Generalized, linear, and mixed models, 2nd edn. John Wiley & Sons, New YorkGoogle Scholar
  60. McQuillin A, Rizig M, Gurling HM (2007) A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics 17:605–617CrossRefPubMedGoogle Scholar
  61. Mizutani R, Yamauchi J, Kusakawa S, Nakamura K, Sanbe A, Torii T, Miyamoto Y, Tanoue A (2009) Sorting nexin 3, a protein upregulated by lithium, contains a novel phosphatidylinositol-binding sequence and mediates neurite outgrowth in N1E-115 cells. Cell Signal 21:1586–1594CrossRefPubMedGoogle Scholar
  62. Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhde TW, Drevets WC, Manji HK (2009) A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 70:699–705CrossRefPubMedGoogle Scholar
  63. Namekata K, Harada C, Guo X, Kimura A, Kittaka D, Watanabe H, Harada T (2012) Dock3 stimulates axonal outgrowth via GSK-3beta-mediated microtubule assembly. J Neurosci 32:264–274CrossRefPubMedGoogle Scholar
  64. Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, Drevets WC, Zarate CA Jr (2014) Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord 16:119–128CrossRefPubMedCentralPubMedGoogle Scholar
  65. Oldfield RC (1971) The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9:97–113CrossRefPubMedGoogle Scholar
  66. Ongur D, Drevets WC, Price JL (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 95:13290–13295CrossRefPubMedCentralPubMedGoogle Scholar
  67. Phatak P, Shaldivin A, King LS, Shapiro P, Regenold WT (2006) Lithium and inositol: effects on brain water homeostasis in the rat. Psychopharmacology (Berl) 186:41–47CrossRefGoogle Scholar
  68. Poo MM (2001) Neurotrophins as synaptic modulators. Nat Rev Neurosci 2:24–32CrossRefPubMedGoogle Scholar
  69. Post RM, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy SL, Leverich GS, Luckenbaugh DA, Rowe M, Pizzarello S, Kupka RW, Grunze H, Nolen WA (2010) Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 71:1176–1186, quiz 1252–3CrossRefPubMedGoogle Scholar
  70. Price JL, Drevets WC (2012) Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 16:61–71CrossRefPubMedGoogle Scholar
  71. Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK (2010) Novel insights into lithium’s mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62:50–60CrossRefPubMedCentralPubMedGoogle Scholar
  72. Rajkowska G (2002) Cell pathology in bipolar disorder. Bipolar Disord 4:105–116CrossRefPubMedGoogle Scholar
  73. Regenold WT (2008) Lithium and increased hippocampal volume-more tissue or more water? Neuropsychopharmacology 33:1773–1774, author reply 1775CrossRefPubMedGoogle Scholar
  74. Schloesser RJ, Martinowich K, Manji HK (2012) Mood-stabilizing drugs: mechanisms of action. Trends Neurosci 35:36–46CrossRefPubMedGoogle Scholar
  75. Schoenbaum G, Roesch MR, Stalnaker TA, Takahashi YK (2009) A new perspective on the role of the orbitofrontal cortex in adaptive behaviour. Nat Rev Neurosci 10:885–892PubMedCentralPubMedGoogle Scholar
  76. Shackman AJ, Salomons TV, Slagter HA, Fox AS, Winter JJ, Davidson RJ (2011) The integration of negative affect, pain and cognitive control in the cingulate cortex. Nat Rev Neurosci 12:154–167CrossRefPubMedCentralPubMedGoogle Scholar
  77. Smith R, Chen K, Baxter L, Fort C, Lane RD (2013) Antidepressant effects of sertraline associated with volume increases in dorsolateral prefrontal cortex. J Affect Disord 146:414–419CrossRefPubMedGoogle Scholar
  78. Takahashi M, Ono J, Harada K, Maeda M, Hackney DB (2000) Diffusional anisotropy in cranial nerves with maturation: quantitative evaluation with diffusion MR imaging in rats. Radiology 216:881–885CrossRefPubMedGoogle Scholar
  79. Thayer JF, Lane RD (2000) A model of neurovisceral integration in emotion regulation and dysregulation. J Affect Disord 61:201–216CrossRefPubMedGoogle Scholar
  80. Timm N, Kim K (2006) Univariate and multivariate general linear models: theory and applications with SAS, 2nd edn. Springer, Berlin / HeidelbergGoogle Scholar
  81. VonDran MW, Singh H, Honeywell JZ, Dreyfus CF (2011) Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion. J Neurosci 31:14182–14190CrossRefPubMedCentralPubMedGoogle Scholar
  82. Voytovych H, Krivanekova L, Ziemann U (2012) Lithium: a switch from LTD- to LTP-like plasticity in human cortex. Neuropharmacology 63:274–279CrossRefPubMedGoogle Scholar
  83. Walton ME, Behrens TE, Buckley MJ, Rudebeck PH, Rushworth MF (2010) Separable learning systems in the macaque brain and the role of orbitofrontal cortex in contingent learning. Neuron 65:927–939CrossRefPubMedCentralPubMedGoogle Scholar
  84. Wang Z, Wang J, Li J, Wang X, Yao Y, Zhang X, Li C, Cheng Y, Ding G, Liu L, Ding Z (2011) MEK/ERKs signaling is essential for lithium-induced neurite outgrowth in N2a cells. Int J Dev Neurosci 29:415–422CrossRefPubMedGoogle Scholar
  85. Wood GE, Young LT, Reagan LP, Chen B, McEwen BS (2004) Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc Natl Acad Sci U S A 101:3973–3978CrossRefPubMedCentralPubMedGoogle Scholar
  86. Wu JC, Buchsbaum M, Bunney WE Jr (2001) Clinical neurochemical implications of sleep deprivation’s effects on the anterior cingulate of depressed responders. Neuropsychopharmacology 25:S74–S78CrossRefPubMedGoogle Scholar
  87. Yoshii A, Constantine-Paton M (2010) Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 70:304–322PubMedCentralPubMedGoogle Scholar
  88. Yuskaitis CJ, Jope RS (2009) Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 21:264–273CrossRefPubMedCentralPubMedGoogle Scholar
  89. Zhang W, Smith A, Liu JP, Cheung NS, Zhou S, Liu K, Li QT, Duan W (2009) GSK3beta modulates PACAP-induced neuritogenesis in PC12 cells by acting downstream of Rap1 in a caveolae-dependent manner. Cell Signal 21:237–245CrossRefPubMedGoogle Scholar
  90. Zhou FQ, Zhou J, Dedhar S, Wu YH, Snider WD (2004) NGF-induced axon growth is mediated by localized inactivation of GSK-3beta and functions of the microtubule plus end binding protein APC. Neuron 42:897–912CrossRefPubMedGoogle Scholar
  91. Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, Damschroder-Williams P, Du J, Zhang L, Manji HK (2005) The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 25:4493–4502CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Francesco Benedetti
    • 1
    • 3
  • Sara Poletti
    • 1
    • 3
  • Daniele Radaelli
    • 1
    • 3
  • Clara Locatelli
    • 1
    • 3
  • Adele Pirovano
    • 1
  • Cristina Lorenzi
    • 1
  • Benedetta Vai
    • 1
    • 3
    • 4
  • Irene Bollettini
    • 1
    • 3
    • 5
  • Andrea Falini
    • 2
    • 3
  • Enrico Smeraldi
    • 1
    • 3
  • Cristina Colombo
    • 1
  1. 1.Department of Clinical NeurosciencesScientific Institute and University Vita-Salute San RaffaeleMilanItaly
  2. 2.Department of NeuroradiologyScientific Institute and University Vita-Salute San RaffaeleMilanItaly
  3. 3.C.E.R.M.A.C. (Centro di Eccellenza Risonanza Magnetica ad Alto Campo)University Vita-Salute San RaffaeleMilanItaly
  4. 4.PhD Program in Evolutionary PsychopathologyLibera Università Maria Ss. AssuntaRomeItaly
  5. 5.PhD Program in Philosophy and Sciences of Mind, Neuroscience sectionUniversity Vita-Salute San RaffaeleMilanItaly

Personalised recommendations